comparemela.com

Latest Breaking News On - பெர்னார்ட் லூயிஸ் ராக்ஸ் - Page 1 : comparemela.com

Truffle Capital & The Institut Pasteur Create SpikImm to Develop Monoclonal Antibodies as an Innovative Treatment For Covid-19

Truffle Capital & The Institut Pasteur Create SpikImm to Develop Monoclonal Antibodies as an Innovative Treatment For Covid-19 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005708/en/ Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of the disease from developing. This immunotherapy offers several therapeutic advantages which have already been proven in clinical trials. Antibodies developed by SpikImm have been generated in the laboratory of Humoral Immunology at the Institut Pasteur through an innovative process enabling the screening and selection of human SARS-CoV-2 neutralizing antibodies. An international patent application has been filed by the Institut Pasteur.

Truffle Capital and Sopra Steria invest €2 million in Particeep

External | what does this mean? This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. Truffle Capital and Sopra Steria invest €2 million in Particeep 16 February 2021 Source: Particeep The fintech Particeep, a leader SaaS distribution solution for financial products and services, announces the arrival of the European fund specialized in fintechs Truffle Capital, and Sopra Steria a European leader in consulting, digital services and software development as minority shareholders. Created in 2013 and based in Paris, the fintech Particeep digitalizes and simplifies the distribution of banking, insurance and savings products. Thanks to Particeep, banks and insurance companies can not only offer their end customers online subscriptions, but also offer distributors and partners controlled and secure access to their offers and associated subscription journeys. Particeep also of

Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies

Press release content from Business Wire. The AP news staff was not involved in its creation. Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies February 1, 2021 GMT Truffle Capital: 1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020 As of today, Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1 st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.